Amgen's Epogen

Health Care Financing Administration publishes final rule providing for reimbursement of home use of epoetin in end-stage renal disease in Jan. 10 Federal Register. Final rule is essentially unchanged from Sept. 4, 1991 interim rule. HCFA notes that facilities generally pay about 10% less than the Medicare reimbursement rate of $11 per 1,000 units for EPO. Amgen "gave surveyed facilities end-of-year rebates ranging from 2% to 8% depending upon the volume of EPO used," HCFA says, concluding that reimbursement of EPO would be adequate to cover other supplies...